1. Chang D, Sharma L, Dela Cruz CS et al. Clinical Epidemiology, Risk Factors, and Control Strategies of Klebsiella pneumoniae Infection. Front. Microbiol 2021; 12: 750662.
2. Dong, N, Yang, X, Chan EW, et al. Klebsiella species: Taxonomy, hypervirulence and multidrug resistance. EBioMedicine 2022; 79: 103998.
3. Janda JM, Abbott SL. The Changing Face of the Family Enterobacteriaceae (Order: “Enterobacterales”): New Members, Taxonomic Issues, Geographic Expansion, and New Diseases and
Disease Syndromes. Clin Microbiol Rev 2021; 34(2): e00174-20.
4. Wyres KL, Lam MMC, Holt, KE. Population genomics of Klebsiella pneumoniae. Nature reviews. Microbiology 2020; 18(6): 344–359.
5. Gu D, Dong N, Zheng Z, et al. A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study. Lancet Infect Dis
2018; 18(1): 37-46.
6. Wyres KL, Nguyen TNT, Lam MMC, et al. Genomic surveillance for hypervirulence and multi-drug resistance in invasive Klebsiella pneumoniae from South and Southeast Asia. Genome Med
2020; 16;12(1): 11.
7. Public Health England. Identification of Enterobacteriaceae. UK Standards for Microbiology Investigations 2015; ID 16 Issue 4.
8. Alves MS, Dias RC, de Castro AC, Riley LW, Moreira BM.. Identification of clinical isolates of indole-positive and indole-negative Klebsiella spp. Journal of clinical microbiology 2006; 44(10):
3640–3646.
9. Appel TM, Quijano-Martínez N, De La Cadena E, Mojica MF, Villegas MV. Microbiological and Clinical Aspects of Raoultella spp. Frontiers in public health 2021; 9: 686789.
10. Jr. WN, Allen, S., Janda, W., Koneman, E., Procop, G., Schreckenberger, et al. Editors The Enterobacteriaceae Koneman’s Color Atlas and Textbook of Diagnostic Microbiology. Seventh edition.
Philadelphia. Wolters Kluwer Health, 2017.
11. Centers for Disease Control and Prevention (CDC), Healthcare-Associated Infections (HAIs), Klebsiella pneumoniae in Healthcare Settings 2023.
12. Argimón S, David S, Underwood A, et al. NIHR Global Health Research Unit on Genomic Surveillance of Antimicrobial Resistance (2021). Rapid Genomic Characterization and Global
Surveillance of Klebsiella Using Pathogenwatch. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73(Suppl_4), S325–S335.
13. Patro LPP, Rathinavelan T. Targeting the Sugary Armor of Klebsiella Species. Frontiers in cellular and infection microbiology 2019;. 9: 367.
14. Wang G, Zhao G, Chao X, Xie L, Wang H. The Characteristic of Virulence, Biofilm and Antibiotic Resistance of Klebsiella pneumoniae. Int J Environ Res Public Health 2020; 28: 17(17).
15. Clegg S, Murphy CN. Epidemiology and Virulence of Klebsiella pneumoniae. Microbiol Spectr 2016; 4(1).
16. Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clinical microbiology reviews 1998; 11(4): 589–603.
17. Patro LPP, Sudhakar KU, Rathinavelan T. K-PAM: a unified platform to distinguish Klebsiella species K- and O-antigen types, model antigen structures and identify hypervirulent strains. Sci
Rep 2020; 7;10(1): 16732.
18. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Healthcare Quality Promotion (DHQP) 2019.
19. Centers for Disease Control and Prevention (CDC), Sexually Transmitted Diseases (STDs) STI Treatment Guidelines, 2021 Diseases Characterized by Genital, Anal, or Perianal Ulcers, Gra-
nuloma Inguinale (Donovanosis).
20. Botelho-Nevers E, Gouriet F, Lepidi H, et al. Chronic nasal infection caused by Klebsiella rhinoscleromatis or Klebsiella ozaenae: two forgotten infectious diseases. Int J Infect Dis 2007; 11(5):
423–429.
21. Yang J, Long H, Hu Y, Feng Y, McNally A, Zong Z. Klebsiella oxytoca Complex: Update on Taxonomy, Antimicrobial Resistance, and Virulence. Clinical microbiology reviews 2022; 35(1):
e0000621.
22. Menozzi MG, Eigner U, Covan S, et al. Two-center collaborative evaluation of performance of the BD phoenix automated microbiology system for identification and antimicrobial suscepti-
bility testing of gram-negative bacteria. Journal of clinical microbiology 2006; 44(11): 4085–4094.
23. World Health Organization (WHO) Report signals increasing resistance to antibiotics in bacterial infections in humans and need for better data (2022).
24. World Health Organization,W. (2023). Antimicrobial Resistance.
25. Martin RM, Bachman MA. Colonization, Infection, and the Accessory Genome of Klebsiella pneumoniae. Frontiers in cellular and infection microbiology 2018; 8,:4.
ENTEROBACTER
KAYNAKLAR
1. Davin-Regli A, Lavigne JP, Pagès JM. Enterobacter spp.: Update on Taxonomy, Clinical Aspects, and Emerging Antimicrobial Resistance. Clinical microbiology reviews 2019; 32(4): e00002-19.
2. UK Standards for Microbiology Investigations Identification of Enterobacteriaceae. Bacteriology – Identification ID 16 Issue no: 4 Issue date: 13.04.15 Page: 1 of 34.
3. Wu W, Feng Y, Zong Z. Precise Species Identification for Enterobacter: a Genome Sequence-Based Study with Reporting of Two Novel Species, Enterobacter quasiroggenkampii sp. nov. and
Enterobacter quasimori sp. nov. mSystems 2020; 4;5(4): e00527-20.
4. Zong, Z, Feng Y, McNally A. Carbapenem and Colistin Resistance in Enterobacter: Determinants and Clones. Trends in microbiology 2021; 29(6): 473–476.
5. Sheng JF, Li JJ, Tu S, et al. blaKPC and rmtB on a single plasmid in Enterobacter amnigenus and Klebsiella pneumoniae isolates from the same patient. Eur J Clin Microbiol Infect Dis. 2012;
31(7): 1585-91.
6. Zhu B, Wang S, Li O, et al. High-quality genome sequence of human pathogen Enterobacter asburiae type strain 1497-78T. J Glob Antimicrob Resist 2017; 8: 104–105.
7. Hoffmann H, Roggenkamp A. Population genetics of the nomenspecies Enterobacter cloacae. Appl Environ Microbiol 2003; 69(9): 5306-18.
8. Bouige A, Fourcade C, Bicart-See A, et al. Characteristics of Enterobacter cloacae prosthetic joint infections. Med Mal Infect 2019 ;49(7): 511-518.
9. Yeh TK, Lin HJ, Liu PY, Wang JH, Hsueh PR. Antibiotic resistance in Enterobacter hormaechei. Int J Antimicrob Agents 2022; 60(4): 106650.
10. Manandhar S, Nguyen Q, Pham DT, et al. A fatal outbreak of neonatal sepsis caused by mcr-10-carrying Enterobacter kobei in a tertiary care hospital in Nepal. J Hosp Infect 2022; 125: 60-66.
11. Ramirez D, Giron M. Enterobacter Infections. [Updated 2023 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.
nih.gov/books/NBK559296/
12. Salimiyan Rizi K, Ghazvini K, Farsiani H. Clinical and pathogenesis overview of Enterobacter infections. Rev Clin Med 2019; 6(4): 146-154.
13. Krzymin´ ska S, Koczura R, Mokracka J, Puton T, Kaznowski A. Isolates of the Enterobacter cloacae complex induce apoptosis of human intestinal epithelial cells. Microb Pathog 2010; 49:
83–89.
14. Paauw A, Caspers MP, Leverstein-van Hall MA, et al. Identification of resistance and virulence factors in an epidemic Enterobacter hormaechei outbreak strain. Microbiology 2009; 155: 1478
–1488.
15. Doijad SP, Gisch N, Frantz R, et al. Resolving colistin resistance and heteroresistance in Enterobacter species. Nat Commun 2023; 14(1): 140.
16. Ioannou P, Vamvoukaki R, Kofteridis DP. Infective endocarditis by Enterobacter cloacae: a systematic review and meta-analysis. Journal of chemotherapy 2022; 34(1): 1–8.
17. Paauw A, Caspers MPM, Schuren FHJ, et al. Genomic diversity within the Enterobacter cloacae complex.. PLoS One 2008; 3: e3018.
18. Abdul-Mutakabbir JC, Alosaimy S, Morrisette T, Kebriaei R, Rybak MJ. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens. Pharmaco-
therapy 2020; 40(12): 1228-1247.
CITROBACTER
KAYNAKLAR
1. Jabeen I, Islam S, Hassan AKMI, Tasnim Z, Shuvo SR. A brief insight into Citrobacter species – a growing threat to public health. Front Antibiot 2023; 2: 1276982.
2. Yao Y, Falgenhauer L, Falgenhauer J, et al. Carbapenem-Resistant Citrobacter spp. as an Emerging Concern in the Hospital-Setting: Results From a Genome-Based Regional Surveillance Study.
Front Cell Infect Microbiol 2021; 11: 744431.
3. Janda JM, Abbott SL, Cheung WK, Hanson DF. Biochemical identification of citrobacteria in the clinical laboratory. J Clin Microbiol. 1994; 32(8): 1850-4.
4. Osei Sekyere J, Reta MA. Global evolutionary epidemiology and resistome dynamics of Citrobacter species, Enterobacter hormaechei, Klebsiella variicola, and Proteeae clones. Environ Micro-
biol 2021; 12: 7412–7431.
5. European Centre for Disease Prevention and Control. Healthcare-associated infections acquired in intensive care units. In ECDC; Annual Epidemiological Report for 2020; ECDC: Sto-
ckholm, Sweden, 2020
6. Yuan C, Yin Z, Wang J, et al. Comparative genomic analysis of Citrobacter and key genes essential for the pathogenicity of citrobacter koseri. Front Microbiol 2019; 10: 2774.
7. Liu L, Zhang L, Zhou H, et al. Antimicrobial Resistance and Molecular Characterization of Citrobacter spp. Causing Extraintestinal Infections. Front Cell Infect Microbiol. 2021; 11: 737636.
8. Jr. WN, Allen, S., Janda, W., Koneman, E., Procop, G., Schreckenberger, et al. Editors The Enterobacteriaceae Koneman’s Color Atlas and Textbook of Diagnostic Microbiology. Seventh edition.
Philadelphia. Wolters Kluwer Health, 2017.
9. Kolínská R, Spanělová P, Dřevínek M, Hrabák J, Zemličková H. Species identification of strains belonging to genus Citrobacter using the biochemical method and MALDI-TOF mass spect-
rometry. Folia Microbiol (Praha). 2015; 60(1): 53-59.
10. Rödel J, Mellmann A, Stein C, et al. Use of MALDI-TOF mass spectrometry to detect nosocomial outbreaks of Serratia marcescens and Citrobacter freundii. Eur J Clin Microbiol Infect Dis
2019; 38(3): 581-591.
11. Nobrega D, Peirano G, Matsumura Y, Pitout JDD. Molecular Epidemiology of Global Carbapenemase-Producing Citrobacter spp. (2015-2017). Microbiol Spectr. 2023; 11(2): e0414422.
12. Manohar, P., Madurantakam Royam, M., Loh, B., Bozdogan, B., Nachimuthu, R., and Leptihn, S.. Synergistic Effects of Phage-Antibiotic Combinations against Citrobacter amalonaticus. ACS
Infect. Dis 2022; 8, 59–65.
13. Yi J, Kim KH. Identification and infection control of carbapenem-resistant Enterobacterales in intensive care units. Acute Crit Care. 2021; 36(3): 175-184.
SERRATIA
KAYNAKLAR
1. Tavares-Carreon F, De Anda-Mora K, Rojas-Barrera IC, Andrade A. Serratia marcescens antibiotic resistance mechanisms of an opportunistic pathogen: a literature review. PeerJ 2023; 11:
e14399.
2. Jr. WN, Allen, S., Janda, W., Koneman, E., Procop, G., Schreckenberger, et al. Editors The Enterobacteriaceae Koneman’s Color Atlas and Textbook of Diagnostic Microbiology. Seventh edition.
Philadelphia. Wolters Kluwer Health, 2017.
3. Nazzaro G, Veraldi S. Serratia marcescens: an Italian story. Int J Dermatol 2017; 56(7): 795-796.
4. Mahlen SD. Serratia infections: from military experiments to current practice. Clin Microbiol Rev 2011; 24(4): 755-91.
5. Anderson MT, Himpsl SD, Mitchell LA, Kingsley LG, Snider EP, Mobley HLT. Identification of distinct capsule types associated with Serratia marcescens infection isolates. PLoS Pathog. 2022;
18(3): e1010423.
6. European Centre for Disease Prevention and Control. Healthcare-associated infections acquired in intensive care units. In ECDC; Annual Epidemiological Report for 2020; ECDC: Sto-
ckholm, Sweden, 2020.
7. Rao K, Seekatz A, Bassis C, Sun Y, Mantlo E, Bachman MA. Enterobacterales Infection after Intestinal Dominance in Hospitalized Patients. mSphere 2020; 5(4):e00450-20.
8. Moles L, Gómez M, Moroder E, et al. Serratia marcescens colonization in preterm neonates during their neonatal intensive care unit stay. Antimicrob Resist Infect Control 2019; 8: 135.
9. Phadke VK, Jacob JT. Marvelous but Morbid: Infective endocarditis due to Serratia marcescens. Infect Dis Clin Pract 2016; 24(3): 143-150.
10. Shah S, Clarke LG, Shields RK. Epidemiology and Clinical Outcomes of Non-HACEK Gram-Negative Infective Endocarditis. Open Forum Infect Dis 2023; 10(3): ofad052.
11. Clements T, Ndlovu T, Khan S, Khan W. Biosurfactants produced by Serratia species: Classification, biosynthesis, production and application. Appl Microbiol Biotechnol 2019; 103(2): 589-
602.
12. Herráez R, Mur A, Merlos A, Viñas M, Vinuesa T. Using prodigiosin against some gram-positive and gram-negative bacteria and Trypanosoma cruzi. J Venom Anim Toxins Incl Trop Dis 2019;
25: e20190001.
13. Stankovic N, Senerovic L, Ilic-Tomic T, Vasiljevic B, Nikodinovic-Runic J. Properties and applications of undecylprodigiosin and other bacterial prodigiosins. Appl Microbiol Biotechnol 2014;
98(9): 3841– 3858.
14. Majumdar R, Crum-Cianflone NF. Necrotizing fasciitis due to Serratia marcescens: case report and review of the literature. Infection 2016; 44(3): 371-7.
15. Zivkovic Zaric R, Zaric M, Sekulic M, Zornic N, et al. Antimicrobial Treatment of Serratia marcescens Invasive Infections: Systematic Review. Antibiotics (Basel). 2023; 12(2): 367